Sezione di Tecnologia e Legislazione Farmaceutiche "M. E. Sangalli", Dipartimento di Scienze Farmaceutiche, Università degli Studi di Milano, via G. Colombo 71, 20133 Milano, Italy; Multiply Labs, 1760 Cesar Chavez Street Unit D, San Francisco, CA 94124, USA.
Dipartimento di Chimica, Materiali e Ingegneria Chimica "G. Natta", Politecnico di Milano, Piazza Leonardo da Vinci 32, 20133 Milano, Italy.
Int J Pharm. 2021 Jan 5;592:119901. doi: 10.1016/j.ijpharm.2020.119901. Epub 2020 Oct 1.
3D printing, and particularly fused deposition modeling (FDM), has rapidly brought the possibility of personalizing drug therapies to the forefront of pharmaceutical research and media attention. Applications for this technology, described in published articles, are expected to grow significantly in 2020. Where are we on this path, and what needs to be done to develop a FDM 2.0 process and make personalized medicines available to patients? Based on literature analysis, this manuscript aims to answer these questions and highlight the critical technical aspects of FDM as an emerging technology for manufacturing safe, high-quality personalized oral drug products. In this collaborative paper, experts from different fields contribute strategies for ensuring the quality of starting materials and discuss the design phase, printer hardware and software, the process, the environment and the resulting products, from the perspectives of both patients and operators.
3D 打印,特别是熔融沉积建模(FDM),迅速将药物治疗个性化的可能性推向了制药研究和媒体关注的前沿。已发表文章中描述了这项技术的应用,预计在 2020 年将显著增长。我们在这条道路上处于什么位置,以及需要做些什么来开发 FDM 2.0 工艺并使个性化药物能够为患者所用?基于文献分析,本文旨在回答这些问题,并强调 FDM 作为一种新兴的制造安全、高质量个性化口服药物产品的技术的关键技术方面。在这篇合作论文中,来自不同领域的专家贡献了确保起始材料质量的策略,并从患者和操作人员的角度讨论了设计阶段、打印机硬件和软件、工艺、环境和最终产品。